Alivus Life Sciences Fair Value
Alivus Life Sciences (ALIVUS) average fair value is ₹1272.33 across 7 valuation models — P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹1430.8 (-11.08%), fair value range ₹8.7–₹3891.78. Read ALIVUS dividend track record for the complete payout history and dividend yield track record.
Fair Value Analysis Export
ALIVUS Fair Value vs Current Price — Valuation Summary
ALIVUS average fair value, fair value range, price gap and valuation status across 7 models: P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Browse Alivus Life Sciences annual reports for revenue, profit, balance sheet and cash flow data.
P/E Based Valuation
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
ALIVUS Fair Value Analysis — Data Sources & Coverage
Alivus Life Sciences financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit Alivus Life Sciences share price today.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
ALIVUS vs Healthcare Sector Peers — P/E, P/B & Market Cap
Alivus Life Sciences P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.